Atrasentan
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
IgA Nephropathy
Conditions
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
Trial Timeline
Mar 15, 2021 → Oct 27, 2026
NCT ID
NCT04573920About Atrasentan
Atrasentan is a phase 2 stage product being developed by Novartis for IgA Nephropathy. The current trial status is active. This product is registered under clinical trial identifier NCT04573920. Target conditions include IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome.
What happened to similar drugs?
6 of 20 similar drugs in IgA Nephropathy were approved
Approved (6) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07319585 | Pre-clinical | Active |
| NCT04573920 | Phase 2 | Active |
Competing Products
20 competing products in IgA Nephropathy